Sana Biotechnology SANA Operating Lease Liabilities (Total)
Operating Lease Liabilities (Total) at other companies
Other financials
Where this comes from
Reported directly by Sana Biotechnology in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiability.
The official record: Sana Biotechnology’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sana Biotechnology's operating lease liabilities (total).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sana Biotechnology's operating lease liabilities (total)?
- Sana Biotechnology (SANA) reported operating lease liabilities (total) of $75.33M in Q1 2026.
- How has Sana Biotechnology's operating lease liabilities (total) changed year-over-year?
- Sana Biotechnology's operating lease liabilities (total) decreased by 17.5% year-over-year, from $91.31M to $75.33M.
- What is the long-term trend for Sana Biotechnology's operating lease liabilities (total)?
- Over 4 years (2021 to 2025), Sana Biotechnology's operating lease liabilities (total) has grown at a -8.2% compound annual growth rate (CAGR), from $110.94M to $78.86M.
- What does operating lease liabilities (total) mean?
- This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.